Follows Agreement on the Improved Pricing of Priadel with the Department of Health and Social Security
Egham, UK – 18 December 2020 – Essential Pharma, an international pharmaceutical generics company dedicated to supplying well-established, “at risk” products to patients across multiple therapeutic areas, welcomes today’s swift and successful conclusion of the Competition and Markets Authority (CMA) inquiry into the continued supply in the UK of Priadel, a lithium-based medicine for the treatment of bipolar disorder.
The outcome follows an agreement between Essential Pharma and the Department of Health and Social Care, which led to an improved price for Priadel meaning it was no longer being sold at a loss in the UK. As a result, Essential Pharma has made formal commitments that are intended to preserve the appropriate and continued supply of Priadel in the UK for the next five years.
The swift conclusion is in the best interests of patients and the UK’s National Health Service (NHS) by providing certainty on the future supply of Priadel.
Ingvild Liborg, Chief Executive of Essential Pharma, said:
“We welcome the swift and successful conclusion of the CMA’s inquiry into Priadel in the UK. This positive outcome for all parties is based on our commitments with regard to continuing the supply of Priadel to patients in the UK. We are happy we have been able to make these commitments as a result of the price agreement made with the Department of Health & Social Care on 5th November 2020, which means that Essential Pharma is no longer supplying Priadel at an unsustainable loss.
“Essential Pharma is committed to its founding principle of supporting patients with continued access to low volume drugs that otherwise may not be available on a sustainable basis and at a fair price. Our commitments are good for the NHS and will give certainty to patients using this important product for years to come.”